scholarly journals Rapid improvement of depressive symptoms in suicide attempters following treatment with milnacipran and tricyclic antidepressants – a case series

2011 ◽  
pp. 723
Author(s):  
Mike Briley ◽  
Gitoh ◽  
Kirino E
Keyword(s):  
Depressive Symptoms ◽  
Tricyclic Antidepressants ◽  
Case Series ◽  
Rapid Improvement ◽  
Suicide Attempters

scholarly journals Symptom Cluster-Matching Antidepressant Treatment: A Case Series Pilot Study

2021 ◽  
Vol 14 (6) ◽  
pp. 526
Author(s):  
Sławomir Murawiec ◽  
Marek Krzystanek
Keyword(s):  
Depressive Symptoms ◽  
Pilot Study ◽  
Antidepressant Treatment ◽  
Case Series ◽  
Symptom Cluster ◽  
Study Results ◽  
Cluster Matching ◽  
The Individual ◽  
Meta Analyses ◽  
Effectiveness Studies

Despite treating depression with antidepressants, their effectiveness is often insufficient. Comparative effectiveness studies and meta-analyses show the effectiveness of antidepressants; however, they do not provide clear indications as to the choice of a specific antidepressant. The rational choice of antidepressants may be based on matching their mechanisms of action to the symptomatic profiles of depression, reflecting the heterogeneity of symptoms in different patients. The authors presented a series of cases of patients diagnosed with depression in whom at least one previous antidepressant treatment was shown to be ineffective before drug targeted symptom cluster-matching treatment (SCMT). The presented pilot study shows for the first time the effectiveness of SCMT in the different clusters of depressive symptoms. All the described patients obtained recovery from depressive symptoms after introducing drug-targeted SCMT. Once validated in clinical trials, SCMT might become an effective and rational method of selecting an antidepressant according to the individual profile of depressive symptoms, the mechanism of their formation, and the mechanism of drug action. Although the study results are preliminary, SCMT can be a way to personalize treatment, increasing the likelihood of improvement even in patients who meet criteria for treatment-resistant depression.

Cochlear Implantation in Children with Postlingual Progressive Steeply Sloping High-Frequency Hearing Loss

2017 ◽  
Vol 28 (10) ◽  
pp. 913-919 ◽  
Author(s):  
Margaret A. Meredith ◽  
Jay T. Rubinstein ◽  
Kathleen C. Y. Sie ◽  
Susan J. Norton
Keyword(s):  
Hearing Loss ◽  
Speech Perception ◽  
Hearing Aids ◽  
Cochlear Implantation ◽  
High Frequency ◽  
Case Series ◽  
Hearing Preservation ◽  
Rapid Improvement ◽  
Retrospective Case ◽  
Monosyllabic Word

Background: Children with steeply sloping sensorineural hearing loss (SNHL) lack access to critical high-frequency cues despite the use of advanced hearing aid technology. In addition, their auditory-only aided speech perception abilities often meet Food and Drug Administration criteria for cochlear implantation. Purpose: The objective of this study was to describe hearing preservation and speech perception outcomes in a group of young children with steeply sloping SNHL who received a cochlear implant (CI). Research Design: Retrospective case series. Study Sample: Eight children with steeply sloping postlingual progressive SNHL who received a unilateral traditional CI at Seattle Children’s Hospital between 2009 and 2013 and had follow-up data available up to 24 mo postimplant were included. Data Collection and Analysis: A retrospective chart review was completed. Medical records were reviewed for demographic information, preoperative and postoperative behavioral hearing thresholds, and speech perception scores. Paired t tests were used to analyze speech perception data. Hearing preservation results are reported. Results: Rapid improvement of speech perception scores was observed within the first month postimplant for all participants. Mean monosyllabic word scores were 76% and mean phoneme scores were 86.7% at 1-mo postactivation compared to mean preimplant scores of 19.5% and 31.0%, respectively. Hearing preservation was observed in five participants out to 24-mo postactivation. Two participants lost hearing in both the implanted and unimplanted ear, and received a sequential bilateral CI in the other ear after progression of the hearing loss. One participant had a total loss of hearing in only the implanted ear. Results reported in this article are from the ear implanted first. Bilateral outcomes are not reported. Conclusions: CIs provided benefit for children with steeply sloping bilateral hearing loss for whom hearing aids did not provide adequate auditory access. In our cohort, significant improvements in speech understanding occurred rapidly postactivation. Preservation of residual hearing in children with a traditional CI electrode is possible.

scholarly journals Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series

2020 ◽  
Vol 4 (2) ◽  
Author(s):  
Kristina E N Clark ◽  
Oliver Collas ◽  
Helen Lachmann ◽  
Animesh Singh ◽  
Jim Buckley ◽  
...  
Keyword(s):  
Bacterial Infections ◽  
Severe Disease ◽  
Ventilatory Support ◽  
Case Series ◽  
Rapid Improvement ◽  
Intensive Care Admission ◽  
Beneficial Effects ◽  
Life Threatening ◽  
Oxygen Requirements ◽  
Subsequent Improvement

Abstract Objectives Anakinra is a selective IL-1 inhibitor, which has been used in the context of secondary haemophagocytic lymphohistiocytosis. Although usually given in the s.c. form, previous anecdotal reports have emphasized its utility when given i.v. Our aim is to report our experience on the beneficial effects of anakinra i.v. in patients with SARS-CoV-2 and evidence of hyperinflammation. Methods We report four patients with severe COVID-19 infection requiring intensive care admission and ventilatory support. Results All four patients showed evidence of deterioration, with hyperferritinaemia and increasing oxygen requirements and with superadded bacterial infections. Upon commencement of anakinra i.v., there was subsequent improvement in the patients clinically, with reduction in ventilatory support and inotropic support, and biochemically, with rapid improvement in inflammatory markers. Conclusion Anakinra is safe to use i.v. in patients with COVID-19 and evidence of superadded bacterial infection. Although its utility has not been confirmed in a randomized trial, current research in the COVID-19 pandemic aims to establish the utility of immunosuppression, including IL-1 blockade, on the outcomes of patients with moderate to severe disease. Our case series supports its use in patients with severe, life-threatening COVID-19 and evidence of hyperinflammation.

Pramipexole: Augmentation in the Treatment of Depressive Symptoms

CNS Spectrums ◽  
2006 ◽  
Vol 11 (3) ◽  
pp. 172-175 ◽  
Author(s):  
Sanjay Gupta ◽  
Jennifer L. Vincent ◽  
Bradford Frank
Keyword(s):  
Depressive Symptoms ◽  
Treatment Regimen ◽  
Rating Scale ◽  
Bipolar Depression ◽  
Case Series ◽  
Unipolar Depression ◽  
Off Label Use ◽  
Retrospective Case ◽  
Off Label ◽  
Hamilton Rating Scale

ABSTRACTWe describe a retrospective case series of three patients, two with bipolar depression and one with unipolar depression. Pramipexole is a Food and Drug Administration-approved antiparkinsonian agent, which, when used to augment antidepressants, would be considered an off-label use and should be discussed with the patient. These patients had robust responses to pramipexole augmentation of their treatment regimen. All three patients had been taking an atypical antipsychotic. The depressive symptoms were evaluated using the Hamilton Rating Scale for Depression.

scholarly journals UVA/Riboflavin Cross-Linking as an Alternative Treatment for Therapeutic Keratoplasty in Corneal Melting

2012 ◽  
Vol 1 (1) ◽  
pp. 61-65 ◽  
Author(s):  
MJ Tassignon ◽  
C Koppen ◽  
N Al-Sabai
Keyword(s):  
Medical Treatment ◽  
Alternative Treatment ◽  
Case Series ◽  
The Other ◽  
Cross Linking ◽  
Corneal Perforation ◽  
Rapid Improvement ◽  
Corneal Ulcers ◽  
Ulcerative Keratitis ◽  
Corneal Melting

ABSTRACT Purpose To demonstrate the effectiveness of UVA/riboflavin cross-linking (CXL) in the treatment of therapy resistant corneal melting of different etiology. Methods This paper describes a series of four cases presenting severe ulcerative keratitis with infectious and noninfectious causes. In spite of intensive medical treatment, corneal melting did develop in all four eyes. CXL was performed to avoid imminent corneal perforation. Results After CXL, there was a rapid improvement in two eyes which healed completely within a month. In the other two eyes, an emergency keratoplasty had to be performed. Conclusion This case series highlights the effectiveness of CXL in the treatment of corneal melting as an addition to our current therapeutic armamentarium. Improvement can be expected in a few days after treatment. CXL can be considered as an adjunct therapy as soon as melting appears in severe corneal ulcers not responding to conventional, intensive treatment. How to cite this article Al-Sabai N, Koppen C, Tassignon MJ. UVA/Riboflavin Cross-Linking as an Alternative Treatment for Therapeutic Keratoplasty in Corneal Melting. Int J Keratoco Ectatic Corneal Dis 2012;1(1):61-65.

scholarly journals Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression—Case Series Study

2020 ◽  
Vol 13 (10) ◽  
pp. 326
Author(s):  
Marek Krzystanek ◽  
Artur Pałasz
Keyword(s):  
Depressive Symptoms ◽  
Side Effects ◽  
Bipolar Depression ◽  
Therapeutic Option ◽  
Case Series ◽  
Mood Stabilizer ◽  
New Drugs ◽  
Case Series Study ◽  
Antidepressant Efficacy

Bipolar disorder is a chronic and remitting mental illness. Antidepressants are not effective in treating acute bipolar depression, and antipsychotic drugs used in the treatment of bipolar depression cause frequent side effects. This situation justifies the search for new drugs as well as the repurposing of drugs used in other indications. In an open and naturalistic serious case study, 4 patients diagnosed with bipolar I disorder, chronically treated with a mood stabilizer, in whom at least two antidepressants were ineffective in the depressive phase, were treated with amantadine. The woman received 100 mg/day and 3 men received the target dose of 200 mg/day. All patients treated with amantadine improved their depressive symptoms after 1 week of treatment. None of them experienced side effects or manic switch. To reduce the risk of a manic switch, the treatment with amantadine was discontinued 2 weeks after the improvement of depressive symptoms, and no recurrence of depressive symptoms was observed. Amantadine may be a further therapeutic option for the treatment of acute bipolar depression. The drug in this indication may act quickly and be well tolerated. Confirmation of the antidepressant efficacy of amantadine in this indication requires replication of the results and conducting clinical trials.

The Role of Natural Products in Treatment of Depressive Disorder

2022 ◽  
Vol 20 ◽  
Author(s):  
Tayebeh Noori ◽  
Antoni Sureda ◽  
Eduardo Sobarzo-Sánchez ◽  
Samira Shirooie
Keyword(s):  
Natural Products ◽  
Depressive Symptoms ◽  
Depressive Disorder ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Tricyclic Antidepressants ◽  
Monoamine Neurotransmitters ◽  
Therapeutic Goals ◽  
Antidepressant Effects ◽  
Potential Use

Abstract: Depressive disorder is one of the most common psychiatric syndromes that, if left untreated, can cause many disturbances in a person's functions. Numerous factors are involved in depression, including inflammation, brain-derived neurotrophic factor (BDNF), GABAergic system, hypothalamic–pituitary–adrenal (HPA) Axis, monoamine neurotransmitters (serotonin (5-HT), noradrenaline, and dopamine). Common treatments for depression are selective serotonin reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors, but these drugs have several side effects such as anxiety, diarrhea, constipation, weight loss, and sexual dysfunctions. These agents only reduce the symptoms and temporarily reduce the rate of cognitive impairment associated with depression. As a result, extensive research has recently been conducted on the potential use of antidepressant and sedative herbs. According to the available data, herbs used in traditional medicine can be significantly effective in reducing depression, depressive symptoms and improving patients' performance. The present study provides a summary of biomarkers and therapeutic goals of depression and shows that natural products such as saffron or genipin, have antidepressant effects. Some of the useful natural products and their mechanisms were evaluated. Data on various herbs and natural isolated compounds reported to prevent and reduce depressive symptoms is also discussed.

Low resilience in suicide attempters: relationship to depressive symptoms

2007 ◽  
Vol 24 (4) ◽  
pp. 273-274 ◽  
Author(s):  
Alec Roy ◽  
Marco Sarchiapone ◽  
Vladimir Carli
Keyword(s):  
Depressive Symptoms ◽  
Suicide Attempters
Sign in / Sign up

Export Citation Format

Share Document